Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 5/20 | 0.34 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.31 |
| ▸ | GLS | O94925 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1326840 | 0.81 | CXCL8 (0.35) | CXCL8GRM7GLS | |
| SCHEMBL7047520 | 0.73 | GABRA1 (0.40) | LMNA | |
| SCHEMBL4652575 | 0.69 | — | — | |
| Hydrochloric Acid SCHEMBL1321778 | 0.64 | RAB9A (0.33) | — | |
| SCHEMBL17034697 | 0.63 | TDP2 (0.35) | — | |
| SCHEMBL13265590 | 0.63 | — | — | |
| Hydrochloric Acid SCHEMBL1326838 | 0.62 | SIGMAR1 (0.33) | — | |
| SCHEMBL30477217 | 0.62 | CYP2A6 (0.36) | — | |
| SCHEMBL26606302 | 0.62 | MAOA (0.34) | — | |
| SCHEMBL4035804 | 0.62 | CYP2A6 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2368896-B1 | Mono-indenyl transition metal compounds and polymerization therewith | EXXONMOBIL CHEM PATENTS INC (US) | 2016-08-24 | — | — | EP | disclosed |
| US-8058461-B2 | Mono-indenyl transition metal compounds and polymerization therewith | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2368896-A1 | Mono-indenyl transition metal compounds and polymerization therewith | ExxonMobil Chemical Patents Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20110213109-A1 | Mono-Indenyl Transition Metal Compounds and Polymerization Therewith | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213109-A1 | Mono-Indenyl Transition Metal Compounds and Polymerization Therewith | ICMT, TERT, PIN1 | CXCL8 3139/4885GRM7 4339/4885GLS 4751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.